Recruiting PHASE3 INTERVENTIONAL 3-arm NCT07133308

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescent Patients With Severe Alopecia Areata With an Open-label Extension Period

Sponsor: Sun Pharmaceutical Industries, Inc.

Conditions Alopecia Areata

Interventions Deuruxolitinib Placebo

Updated 2 times since 2025 Last updated: Jan 27, 2026 Started: Aug 5, 2025 Primary completion: May 31, 2028 Completion: May 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Alopecia Areata, this trial is actively recruiting participants. The trial is conducted by Sun Pharmaceutical Industries, Inc. and has accumulated 2 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3
Sep 2025 — Feb 2026 [monthly]

Recruiting PHASE3

First recorded

Aug 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Pharmaceutical Industries, Inc.

Data source: Sun Pharmaceutical Industries Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Auburn Hills, United States , Bakersfield, United States , Birmingham, United States , Boise, United States , Bryant, United States , Calgary, Canada , Cary, United States , Charlotte, United States , Chicago, United States , Clarksville, United States and 45 more locations